
McKesson Corporation (MCK)
$
860.16
-3.40 (-0.40%)
Key metrics
Financial statements
Free cash flow per share
81.9481
Market cap
108.6 Billion
Price to sales ratio
0.2729
Debt to equity
-6.6441
Current ratio
0.8762
Income quality
2.3037
Average inventory
26.6 Billion
ROE
-2.4527
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides a wide range of healthcare services both in the United States and internationally. The company operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment is involved in the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, along with other healthcare-related products. Additionally, this segment offers practice management, technology, clinical support, and business solutions tailored for community-based oncology and other specialty practices. It also provides consulting, outsourcing, technological, and various services while selling financial, operational, and clinical solutions to pharmacies. The International segment serves wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on distributing medical-surgical supplies, logistics, and other essential services to healthcare providers. Meanwhile, the RxTS segment caters to biopharma and life sciences partners, addressing medication challenges throughout patient journeys; it connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions while also providing third-party logistics and wholesale distribution support solutions. The company reported depreciation and amortization expenses of $636,000,000.00 reflecting the wear and tear of its assets. Its selling, general, and administrative expenses total $8,022,000,000.00 indicating operational overhead costs. The interest income earned amounting to $173,000,000.00 showcases its financial investments. Overall, the total costs and expenses for the company are $354,679,000,000.00 reflecting comprehensive spending, while the EBITDA stands at $5,251,000,000.00 a key indicator of the company's operational profitability. In the financial marketplace, the stock is priced at $698.31 positioning it in the higher-end market. It has an average trading volume of 720,872.00 indicating moderate liquidity in its trading activities. With a significant market capitalization of $106,166,664,684.00 McKesson Corporation establishes itself as a dominant player in the healthcare industry. The company is an essential participant in the Medical - Distribution industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its domain.
Investing in McKesson Corporation (MCK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict McKesson Corporation stock to fluctuate between $637 (low) and $999 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-03-30, McKesson Corporation's market cap is $106,166,664,684, based on 123,426,647 outstanding shares.
Compared to Eli Lilly & Co., McKesson Corporation has a Lower Market-Cap, indicating a difference in performance.
McKesson Corporation pays dividends. The current dividend yield is 0.32%, with a payout of $0.82 per share.
To buy McKesson Corporation (MCK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MCK. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
McKesson Corporation's last stock split was 2:1 on 1998-01-05.
Revenue: $359,051,000,000 | EPS: $25.86 | Growth: 14.73%.
Visit https://www.mckesson.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $999 (2026-03-03) | All-time low: $192.38 (2021-08-10).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

defenseworld.net
Barlow Wealth Partners LLC increased its stake in shares of McKesson Corporation (NYSE: MCK) by 7.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,123 shares of the company's stock after acquiring an additional 1,236 shares during

zacks.com
CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.

defenseworld.net
McKesson Corporation (NYSE: MCK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seventeen ratings firms that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year target

zacks.com
McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.

zacks.com
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

seekingalpha.com
McKesson Corporation (MCK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

seekingalpha.com
McKesson Corporation (MCK) Presents at Leerink Global Healthcare Conference 2026 Transcript

fxempire.com
McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.

seekingalpha.com
McKesson Corporation shares are now fairly valued after a 16% price increase, prompting a Hold rating. Strong Q3 results were driven by 11% revenue growth and a 37% surge in the Oncology & Multispeciality segment, aided by M&A. Management raised FY2026 guidance, with EPS now expected at $38.80–39.20 and revenue growth at 12–16%.

zacks.com
McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.
See all news